Berkeley Lights announced Amgen has purchased additional Beacon Opto-Fluidic Platforms. The Beacon platform reduces workflow lead times and increases capacity by transforming currently fragmented microfluidic workflows into automated nanofluidic workflows. Amgen, which collaborated with BLI to develop this technology, will now expand its usage to cell line development, antibody discovery, and other research activities.
"We are pleased to see Amgen, a leader and innovator in the pharmaceutical industry, expand its adoption of the Beacon platform across discovery and development processes," Eric Hobbs, PhD, BLI chief executive officer said. "BLI is dedicated to improving biological workflows in collaboration with our partners."
Berkeley Lights develops and commercializes platforms on which many bio-pharmaceutical, genomic, and cellular therapy applications will run.